Trioday is a medication that includes three active components: Tenofovir, Lamivudine, and Efavirenz, which is utilized to treat HIV in adult patients.
Tenofovir and Lamivudine are classified as nucleotide reverse transcriptase inhibitors (NRTIs), whereas Efavirenz is categorized as a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Tenofovir disoproxil fumarate is first converted into tenofovir, an acyclic nucleotide analogue of adenosine monophosphate, and subsequently transforms into its active metabolite, tenofovir diphosphate. Within the cells, lamivudine is metabolized into its active form, 5-triphosphate. The primary metabolic pathways of Efavirenz produce three hydroxylated metabolites: 8-hydroxy efavirenz, 8,14-dihydroxyefavirenz, and 7-hydroxyefavirenz.
Trioday contains the recommended dosages for its active ingredients: 300mg of Tenofovir, 300mg of Lamivudine, and 600mg of Efavirenz.
While Tenofovir and Lamivudine can be administered with or without food, it is recommended to take Efavirenz at bedtime on an empty stomach to reduce potential side effects. Thus, Trioday should be taken orally before bedtime and without food.
Please be aware that a physician experienced in HIV treatment must prescribe this therapy.
The most frequently reported side effects of Trioday (occurring in over 5% of patients, varying from mild to severe) include: asthenia, coughing, depression, diarrhea, dizziness, fatigue, general weakness, headache, insomnia, nasal symptoms, nausea, pain, and skin rash.
Before beginning the treatment, you should consult your physician. Trioday may be contraindicated for patients with the following conditions in their current or past medical history: individuals under 18; impaired kidney function; hypersensitivity, intolerance, or life-threatening allergic reactions to any components of the drug; peripheral neuropathy; simultaneous use of terfenadine, astemizole, cisapride, midazolam, and triazolam.